Keeping a Buy rating and $155 price target on Blueprint Medicines (BPMC), Stifel says the market is disappointed that 2025 Ayvakit guidance brackets consensus, given those same consensus sources ...

Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners and Miller Buckfire & Co., LLC business divisions ...

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Hold rating ... focusing on stocks such as Blueprint Medicines, Kura Oncology, and ALX Oncology Holdings.

What should I know about this firm? Stifel, Nicolaus & Co. Inc. offers investment advising services that let individuals choose the level of control they have over their portfolio. Everyday ...

Onsemi (NASDAQ:ON – Get Free Report) had its price objective reduced by research analysts at Stifel Nicolaus from $60.00 to $52.00 in a research note issued on Tuesday,Benzinga reports.

Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners and Miller Buckfire & Co., LLC business divisions ...